Professor, Monash University
Chris Langmead is Professor, Deputy Director, and Better Medicines Theme Leader of the Neuromedicines Discovery Centre at the Monash Institute of Pharmaceutical Sciences (MIPS), a collaborative venture targeting new medicines development for poorly-treated mental health disorders. He is also the co-founder and CEO of Phrenix Therapeutics, which is developing next-generation therapeutics for schizophrenia.
The tricky economics of subsidising psychedelics for mental health therapy
May 01, 2023 06:58 am UTC| Economy
Australia is the worlds first country to legalise the medical use of psychedelics. But not everyone is sure the timing is right. There are still major issues to work out for this move to benefit those most in need. In...
South Africa’s plan to move away from coal: 8 steps to make it succeed
Germany lowers voting age to 16 for the European elections
IceCube researchers detect a rare type of energetic neutrino sent from powerful astronomical objects